Recombinant TNFRSF8 (Brentuximab Biosimilar) anticorps

N° du produit ABIN7581724

L’anticorps Human Monoclonal anti-TNFRSF8 (Brentuximab Biosimilar) a été validé pour ELISA, BLI, FACS, Func et SPR. Il convient pour détecter TNFRSF8 (Brentuximab Biosimilar) dans des échantillons de Humain.

Aperçu rapide pour Recombinant TNFRSF8 (Brentuximab Biosimilar) anticorps (ABIN7581724)

Antigène: TNFRSF8 (Brentuximab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Human

Clonalité: Monoclonal

Conjugué: Cet anticorp TNFRSF8 (Brentuximab Biosimilar) est non-conjugé

Application: ELISA, Bio-Layer Interferometry (BLI), Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)

Détail du produit anti-TNFRSF8 (Brentuximab Biosimilar) anticorps

Expression System: CHO Cells

Fonction: Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab)

Séquence: QIQLQQSGPE VVKPGASVKI SCKASGYTFT DYYITWVKQK PGQGLEWIGW IYPGSGNTKY NEKFKGKATL TVDTSSSTAF MQLSSLTSED TAVYFCANYG NYWFAYWGQG TQVTVSAAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG,DIVLTQSPAS LAVSLGQRAT ISCKASQSVD FDGDSYMNWY QQKPGQPPKV LIYAASNLES GIPARFSGSG SGTDFTLNIH PVEEEDAATY YCQQSNEDPW TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC

Attributs du produit: Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.38 kDa.

Pureté: >95 %

Isotype: IgG1

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Commentaires:

Therapeutic Agents by Target and Mechanism: CD30 inhibitors

Conditions: Anaplastic Large Cell Lymphoma Hematologic malignancies Hodgkin Lymphoma

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Concentration: 1 mg/mL

Buffer: 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2

Stock: 4 °C,-80 °C

Stockage commentaire: +4°C,-80°C

Détails sur TNFRSF8 (Brentuximab Biosimilar)

Antigène: TNFRSF8 (Brentuximab Biosimilar)

Classe de substances: Biosimilar

Sujet: Synonyms: TNFRSF8

Poids moléculaire: 145.38 kDa

UniProt: P28908